Cathy Eng, MD, FACP | Authors

January 15, 2018

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the BRAF-mutant colorectal cancer patient population.

November 30, 2017

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.

January 22, 2016

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).

January 22, 2016

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).